-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of "Buy" From Analysts
DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of "Buy" From Analysts
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $43.33.
DICE has been the subject of a number of analyst reports. HC Wainwright initiated coverage on DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 target price for the company. Stifel Nicolaus initiated coverage on DICE Therapeutics in a research note on Tuesday, September 6th. They set a "buy" rating and a $37.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company.
Get DICE Therapeutics alerts:DICE Therapeutics Trading Down 0.2 %
DICE Therapeutics stock opened at $19.98 on Wednesday. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $40.50. The stock has a 50 day moving average of $18.22 and a two-hundred day moving average of $17.68. The stock has a market capitalization of $763.46 million and a price-to-earnings ratio of -5.23.
Hedge Funds Weigh In On DICE Therapeutics
Hedge funds have recently bought and sold shares of the company. Prospera Financial Services Inc purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Amalgamated Bank purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Legal & General Group Plc increased its stake in DICE Therapeutics by 265.1% in the 2nd quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock valued at $74,000 after purchasing an additional 3,459 shares in the last quarter. Virtus ETF Advisers LLC increased its position in DICE Therapeutics by 18.5% during the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company's stock worth $116,000 after buying an additional 1,166 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in DICE Therapeutics during the second quarter worth $131,000. 95.42% of the stock is owned by hedge funds and other institutional investors.About DICE Therapeutics
(Get Rating)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Featured Stories
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $43.33.
據MarketBeat.com報道，Dice治療公司(納斯達克代碼：DICE-GET評級)從追蹤該公司的六位分析師那裏獲得了“買入”的平均評級。六位投資分析師對該股的評級為買入。在去年更新了該股覆蓋範圍的經紀商中，平均12個月的價格目標是43.33美元。
DICE has been the subject of a number of analyst reports. HC Wainwright initiated coverage on DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 target price for the company. Stifel Nicolaus initiated coverage on DICE Therapeutics in a research note on Tuesday, September 6th. They set a "buy" rating and a $37.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company.
Dice已經成為了許多分析師報告的主題。HC Wainwright在7月18日星期一的一份研究報告中開始了對DICE治療的報道。他們為該公司設定了“買入”評級和40.00美元的目標價。Stifel Nicolaus在9月6日星期二的一份研究報告中開始了對DICE治療的報道。他們為該公司設定了“買入”評級和37.00美元的目標價。最後，坎託·菲茨傑拉德在9月14日星期三的一份研究報告中開始了對DICE治療的報道。他們為該公司設定了“增持”評級和36.00美元的目標價。
DICE Therapeutics Trading Down 0.2 %
Dice Treeutics股價下跌0.2%
DICE Therapeutics stock opened at $19.98 on Wednesday. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $40.50. The stock has a 50 day moving average of $18.22 and a two-hundred day moving average of $17.68. The stock has a market capitalization of $763.46 million and a price-to-earnings ratio of -5.23.
週三，Dice治療公司的股票開盤報19.98美元。Dice Treateutics的12個月低點為12.64美元，12個月高位為40.50美元。該股的50日移動均線切入位為18.22美元，200日移動均線切入位為17.68美元。該股市值為7.6346億美元，市盈率為-5.23。
Hedge Funds Weigh In On DICE Therapeutics
對衝基金入股Dice Treeutics
About DICE Therapeutics
關於骰子治療公司
(Get Rating)
(獲取評級)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Dice Treateutics，Inc.是一家生物製藥公司，建立了各種口服治療候選藥物，用於治療免疫學和其他治療領域的慢性病。其平臺DELSCAPE旨在發現選擇性口服小分子，以與系統生物學一樣有效地調節蛋白質-蛋白質相互作用(PPI)。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- 免費獲取StockNews.com關於DICE治療(DICE)的研究報告
- 克羅格百貨是你的一站式消費者史泰博股票
- Adobe為投資者完善Facebook工廠的藝術
- 税收抵免是《降低通貨膨脹法案》中的激勵措施
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受DICE治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Dice Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧